Understanding why CLL patients stop responding to treatment, and options for salvage therapies

Jacqueline Barrientos, MD, from the North Shore-Long Island Jewish Health System in New York, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides details of a current trial comparing two treatments that work on different pathways (PI3K and BTK B-cell inhibitors), with the goal of understanding the best salvage options following treatment failure.

Share this video  
Similar topics